Lamisil At is a drug owned by Karo Healthcare Inc. It is protected by 3 US drug patents filed in 2013 out of which all have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Apr 28, 2015. Details of Lamisil At's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
|
US5681849 (Pediatric) | Pharmaceutical composition for topical applications |
Apr, 2015
(9 years ago) |
Expired
|
| US5681849 | Pharmaceutical composition for topical applications |
Oct, 2014
(10 years ago) |
Expired
|
|
US5856355 (Pediatric) | Pharmaceutical composition |
Nov, 2012
(12 years ago) |
Expired
|
US patents provide insights into the exclusivity only within the United States, but Lamisil At is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Lamisil At's family patents as well as insights into ongoing legal events on those patents.
Lamisil At's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Lamisil At's generic launch date based on the expiry of its last outstanding patent is estimated to be Apr 28, 2015 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Lamisil At Generics:
There are no approved generic versions for Lamisil At as of now.
About Lamisil At
Lamisil At is a drug owned by Karo Healthcare Inc. Lamisil At uses Terbinafine as an active ingredient. Lamisil At was launched by Karo Hlthcare in 2006.
Approval Date:
Lamisil At was approved by FDA for market use on 24 July, 2006.
Active Ingredient:
Lamisil At uses Terbinafine as the active ingredient. Check out other Drugs and Companies using Terbinafine ingredient
Dosage:
Lamisil At is available in gel form for topical use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 1% | GEL | Over the counter | TOPICAL |
Lamisil At is a drug owned by Karo Healthcare Inc. It is protected by 2 US drug patents filed in 2013 out of which all have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Apr 28, 2015. Details of Lamisil At's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
|
US5681849 (Pediatric) | Pharmaceutical composition for topical applications |
Apr, 2015
(9 years ago) |
Expired
|
| US5681849 | Pharmaceutical composition for topical applications |
Oct, 2014
(10 years ago) |
Expired
|
US patents provide insights into the exclusivity only within the United States, but Lamisil At is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Lamisil At's family patents as well as insights into ongoing legal events on those patents.
Lamisil At's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Lamisil At's generic launch date based on the expiry of its last outstanding patent is estimated to be Apr 28, 2015 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Lamisil At Generics:
There are no approved generic versions for Lamisil At as of now.
About Lamisil At
Lamisil At is a drug owned by Karo Healthcare Inc. Lamisil At uses Terbinafine Hydrochloride as an active ingredient. Lamisil At was launched by Karo Hlthcare in 2000.
Approval Date:
Lamisil At was approved by FDA for market use on 17 March, 2000.
Active Ingredient:
Lamisil At uses Terbinafine Hydrochloride as the active ingredient. Check out other Drugs and Companies using Terbinafine Hydrochloride ingredient
Dosage:
Lamisil At is available in solution form for topical use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 1% | SOLUTION | Over the counter | TOPICAL |